Home > VICTORIA > Presentations

Presentations

Late-Breaking Clinical Trial Presentation

The VICTORIA trial was presented as a Late-Breaking Clinical Trial on March 28, 2020 at the virtual American College of Cardiology’s 69th Annual Scientific Session Together With World Congress of Cardiology (ACC.20/WCC).

---

Other Presentations

ESC HFA Discoveries 2020

• Effects of Vericiguat on Left Ventricular Structure and Function in Patients with Heart Failure with Reduced Ejection Fraction: The VICTORIA Echocardiographic Substudy (PDF)
• NT-proBNP and Clinical Outcomes in VICTORIA (PDF)

ESC Congress 2020

• Bayer Symposium: Therapeutic Advances in HFrEF Patients who Have had a Previous Worsening HF Event (PDF)

HFSA Virtual Annual Scientific Meeting 2020

• Effect of Vericiguat in VICTORIA According to Guideline Directed Medical Therapy (PDF)

• VICTORIA Symposium
  • Defining an Optimal Standard of Background Medical Care: Insights from VICTORIA (PDF)
  • Where Does Vericiguat Fit in the Contemporary Standard of Care Management of Heart Failure (PDF)

• Posters
  • Non-Participation in a Heart Failure Clinical Trial: Perspectives and Opportunities from the VICTORIA Trial and Simultaneous Registry (PDF)
  • Medical Therapy During Hospitalization for Heart Failure with Reduced Ejection Fraction: The VICTORIA Registry (PDF)

MedEd Talks Podast

• The Clinical Evidence: Efficacy and Safety of sGC Modulators in Heart Failure with Reduced Ejection Fraction with Drs. Paul Armstrong and Javed Butler
• sGC Modulators: Unique Mechanism of Action and Rationale for Use in Heart Failure with Drs. Paul Armstrong and Carolyn Lam
• sGC Modulators: Role in Current Treatment Paradigms for Heart Failure with Drs. Paul Armstrong and Javed Butler
• Heart Failure Management: Guideline-directed Therapy and Unmet Needs with Drs. Paul Armstrong and Carolyn Lam

ACC.21 Scientific Sessions

• Presentations
  • Coronary Artery Disease and Cardiovascular Outcomes in Heart Failure: Insights from the Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (PDF)
• Posters
  • Baseline Cardiac Troponin T, Clinical Outcomes and Vericiguat Treatment Effect in Heart Failure with Reduced Ejection Fraction Study: Insights from the VICTORIA Trial (PDF)
  • Coronary Artery Disease and Cardiovascular Outcomes in Heart Failure: Insights from the Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (PDF)

ESC HFA 2021

• Clinical Outcome Predictions for the VICTORIA Trial (PDF)
• Vericiguat in Patients with Atrial Fibrillation and Heart Failure with Reduced Ejection Fraction: Insights from the VICTORIA trial (PDF)
• Change in NT-proBNP and Clinical Outcomes in the Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) (PDF)
• Blood Pressure and Safety Outcomes with Vericiguat in the VICTORIA Trial (PDF)